Prostate cancer PET bioprobes: Synthesis of [18F]-radiolabeled hydroxyflutamide derivatives
摘要:
Approximately 80-90% of prostate cancers are androgen dependent at initial diagnosis. The androgen receptor (AR) is present in most advanced prostate cancer specimens and is believed to have a critical role in its development. Today, treatment of prostate cancer is done by inhibition of AR using antiandrogens such as flutamide (pro-drug of hydroxyflutamide), nilutamide, and bicalutamide. However, there is currently no noninvasive imaging modalities to detect, guide, and monitor specific treatment of AR-positive prostate cancer. (R)-3-Bromo-N-(4-fluoro-3-(trifluoromethy, phenyl)-2-hydroxy-2-methyl-propanamide [F-18]-1 and N-(4fluoro-3-(trifluoromethyl)phenyl)-2-hydroxy-2-methylpropanamide [F-18]-2, derivatives of hydroxyflutamide, were synthesized as a fluorine-containing imaging agent candidates. A three-step fluorine-18 radiosynthesis route was developed, and the compounds were successfully labeled with a 10 +/- 3% decay corrected radiochemical yield, 95% radiochemical purity, and a specific activity of 1500 +/- 200 Ci/mmol end of bombardment (n = 10). These labeled biprobes not only may enable for the future quantitative molecular imaging of AR-positive prostate cancer using positron emission tomography but may also allow for image-guided treatment of prostate cancer. (c) 2005 Elsevier Ltd. All rights reserved.
cobalt precursor can be activated for asymmetric hydrogenation catalysis by using the traditional ligands developed for the precious metals. Zuo et al. (p. 1080) focused on iron, demonstrating a highly effective asymmetric transfer hydrogenationcatalyst that uses a ligand rationally designed after careful mechanistic study. Jagadeesh et al. (p. 1073) prepared supported ironcatalysts that selectively reduce
Activated Mont K10-Carbon supported Fe2O3: A versatile catalyst for hydration of nitriles to amides and reduction of nitro compounds to amines in aqueous media
作者:TASKIA RAHMAN、GEETIKA BORAH、PRADIP K GOGOI
DOI:10.1007/s12039-021-01888-4
日期:2021.3
consecutive cycles without compromising its catalytic proficiency. Graphical abstract Activated Mont K10 carbon-supported Fe2O3 is a very efficient and versatile heterogeneous catalytic system for hydration of nitriles to amides and reduction of nitro compounds to amines and can be reused up to six consecutive cycles without significant loss in catalytic activity.
通过将腈水合成酰胺并将硝基化合物还原成胺的实验可行方案,将氧化铁成功负载在活性粘土/碳上。所制备的催化剂已通过XPS,SEM-EDX,TEM,TGA,BET表面积测量和粉末X射线衍射(PXRD)进行了广泛表征。通过将水用作两种反应的绿色溶剂,可以将各种各样的底物以良好或极好的收率转化为所需的产物。该催化剂可循环使用,最多可连续使用六个循环,而不会影响其催化能力。 图形概要 活化的Mont K10碳负载的Fe 2 O 3是一种非常有效且用途广泛的非均相催化系统,用于将腈水合成酰胺并将硝基化合物还原成胺,并且可以重复使用多达六个连续周期,而不会显着降低催化活性。
WO2007/57909
申请人:——
公开号:——
公开(公告)日:——
Androgen-Receptor (AR) Ligands for Use in the Treatment and Diagnosis of AR-Related Pathologies
申请人:Mishani Eyal
公开号:US20090226368A1
公开(公告)日:2009-09-10
The present invention discloses novel compounds and compositions suitable for the treatment of androgen related pathologies. The invention also provides diagnostic compositions for the diagnosis or monitoring of such androgen pathologies.
[EN] ANDROGEN-RECEPTOR (AR) LIGANDS FOR USE IN THE TREATMENT AND DIAGNOSIS OF AR-RELATED PATHOLOGIES<br/>[FR] LIGANDS DU RECEPTEUR DES ANDROGENES (AR) A UTILISER LORS DU TRAITEMENT ET DU DIAGNOSTIC DE PATHOLOGIES LIEES A L'AR
申请人:HADASIT MED RES SERVICE
公开号:WO2007057909A1
公开(公告)日:2007-05-24
[EN] The present invention discloses novel compounds and compositions suitable for the treatment of androgen related pathologies. The invention also provides diagnostic compositions for the diagnosis or monitoring of such androgen pathologies. [FR] La présente invention concerne de nouveaux composés et compositions appropriés lors du traitement de pathologies liées aux androgènes. L'invention porte également sur des compositions diagnostiques destinées au diagnostic et à la surveillance de ces pathologies liées aux androgènes.